They ran four parallel studies based on different patient profiles: ADM trial: Patients with type 2 diabetes (T2D), comparing newer GLP-1 RAs to older GLP-1 RAs, sulfonylureas, and other anti-diabetic medications (ADMs)
Common side effects include: Nasopharyngitis and upper respiratory tract infections the most frequently reported adverse effects (mechanism not fully established) Headache and dizziness reported in some patients, particularly during the initial weeks of treatment Gastrointestinal symptoms such as nausea or constipation, though these are generally mild Less common but important safety considerations include: Hypoglycaemia : Although the risk is low when a gliptin is used alone or with metformin, it increases when combined with a sulfonylurea or insulin
The abbreviation BPC stands for Body Protection Compound and stems from its potential to enhance regenerative processes in animals
Can you apply NAD+ topically
[1] [2] [12] The best supporting evidence is indirect: in STEP 4 and SURMOUNT-4, people who stopped these medications regained most of their lost weight, while people who continued kept their results